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We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antitu-
berculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide
and ethambutol in urine. Peak concentration and exposure were reduced for rifampin, and rapid acetylators
of isoniazid had lower drug levels. HIV and HIV-tuberculosis patients who have diarrhea and cryptosporidial
infection exhibit decreased bioavailability of antituberculosis drugs.
Most patients with tuberculosis (TB) but without other ill-
nesses absorb antimycobacterial drugs reliably (1, 5). However,
patients with advanced human immunodeficiency virus (HIV)
disease with or without diarrhea may not adequately absorb
anti-TB drugs (3, 13–15). Also, the degrees of malabsorption
appear to differ across populations (4, 6, 17, 19). We recently
observed that HIV-infected patients with and without TB had
malabsorption of rifampin (RMP) and isoniazid (INH), as
determined on the basis of the urinary excretion of the drugs
(7). We further wanted to evaluate the pharmacokinetics of
RMP and INH in HIV-infected patients with and without TB
in relation to the acetylator status of INH. We also wanted to
study the absorption of pyrazinamide (PZA) and ethambutol
(EMB) by estimating the percentage of the dose excreted in
urine, which has not been previously reported.
The study was conducted at the Government Hospital for
Thoracic Medicine, Tambaram, Chennai, India. The partici-
pants comprised 13 HIV-seronegative, pulmonary TB patients
(group 1), 13 patients with advanced HIV infection (group 2),
and 15 patients with HIV-TB (group 3). These study subjects
were distinct from those reported earlier (7). Participants in
groups 2 and 3 had history of recurrent episodes of watery
stools six to eight times a day for at least 10 consecutive days in
a month at the start of the study. All participants in groups 1
and 3 were sputum smear positive for acid-fast bacilli and were
receiving standard anti-TB regimens. None of the patients in
group 1 had complaints of diarrhea or vomiting for at least 3
days before start of the study. The study was approved by the
Institutional Ethics committee, and informed written consent
was obtained from all the patients.
All the patients received RMP (450 mg), INH (600 mg),
PZA (1,500 mg), and EMB (1,200 mg) orally, and blood sam-
ples were collected at 1, 2, 3, 6, and 8 h after drug administra-
tion. Urine excreted up to 8 h after drug administration was
also collected.
The concentrations of RMP and INH in plasma and of PZA
and pyrazinoic acid (PZC) and EMB in urine were estimated
using techniques previously described (8, 9, 10, 12). The INH
acetylator status was also determined (16). All estimations
were undertaken after coding the samples.
Certain pharmacokinetic variables were calculated on the
basis of plasma concentrations of RMP and INH by non-
compartmental methods using WinNonlin software (Pharsight
Corporation, Mountain View, Calif.). The percentages of the
doses of PZA (PZA and PZC) and EMB excreted in urine
were also calculated. Analysis of data was performed using
SPSS (version 10.5) software.
The baseline demographic and laboratory data of all study
participants are shown in Table 1. The mean plasma RMP
concentrations at various time points were significantly lower
in both groups of HIV-positive patients than in TB patients (P
 0.05). There was a significant decrease in mean peak con-
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TABLE 1. Baseline demographic characteristics of
study participants
Characteristic
Value for groupa
Pulmonary TB
(n  13) HIV (n  13) HIV-TB (n  15)
Mean age (yr) 40 (28–50) 30 (25–38) 38 (29–50)
Mean body wt (kg) 43 (32–65) 42 (34–50) 42 (23–62)
Mean CD4 cell
count (cells/mm3)
98 (4–255) 60 (15–330)
INH acetylator status
(no. of participants)
Slow 8 4 7
Rapid 5 9 8
a Ranges are given in parentheses.
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centration of drug in plasma (Cmax) and exposure (area under
the time curve from 0 to 8 h [AUC0–8] and AUC0–) accom-
panied by a significant increase in clearance of RMP with HIV
and HIV-TB patients compared to the results seen with TB
patients (P 0.05) (Table 2). The INH concentrations in rapid
acetylators for both the HIV groups of patients were lower
than those seen with TB patients (P  0.05). Although mean
Cmax and AUC values of INH were lower and mean clearance
values of INH were higher in HIV and HIV-TB patients than
in TB patients, the differences were not statistically significant.
The differences between HIV (with and without TB) and TB
patients were more pronounced with rapid than with slow
acetylators of INH (Table 3 and Table 4).
The percentages of the doses of PZA (PZA and PZC) and
EMB excreted in urine were reduced by 35 and 43% and by 48
and 19% in patients with HIV and HIV-TB, respectively, com-
pared to the results seen with TB patients.
Stool examination for opportunistic enteric pathogens was
performed for seven patients with HIV and nine patients with
HIV-TB. All 16 patients had Cryptosporidium parvum in their
stool samples.
Response to RMP-based antimycobacterial therapy is gen-
erally good in HIV-infected patients with TB (18). However,
this study demonstrated that the bioavailability of RMP in
HIV-infected patients with and without TB was decreased, as
evidenced by a significant reduction in peak concentration and
exposure. Similar findings have been reported by Sahai et al.
(17), who conducted a pharmacokinetic study of Canadian
subjects with HIV infection. Low concentrations of RMP in
blood could be due to malabsorption of the drug (2). Also,
cryptosporidiosis has been suggested as one of the specific
factors that may play a role in drug malabsorption in AIDS
patients (11). Acetylator status had an impact on the bioavail-
ability of INH in HIV-positive patients. While the decreases in
Cmax values in rapid acetylators of HIV and HIV-TB patients
were 34 and 36%, respectively, compared to the results seen
with TB patients, the corresponding values were 11 and 22%
for slow acetylators of INH. Similar observations were made
with respect to AUC values.
Our study further showed that the absorption of PZA and
EMB is affected in patients with HIV infection, since the per-
centage of the dose excreted in urine was significantly lower
than that seen with TB patients. This is in agreement with
results reported by others (3, 6, 13, 17).
Of the 15 patients with HIV-TB studied, 7 had been admit-
ted with a second episode of TB. All of them had received
supervised anti-TB therapy during the first episode. All seven
patients had peak plasma RMP concentrations below 5 g/ml,
a value which is lower than the therapeutic range of the drug
(8 to 24 g/ml) (3). Further, urinary excretion of PZA and
EMB was low, suggesting that poor outcome of treatment with
these drugs could be due to malabsorption and decreased
bioavailability of these drugs. Therapeutic drug monitoring
may be considered for patients with suboptimal response to
treatment.
In conclusion, our study has found definitive evidence of
malabsorption of anti-TB drugs, particularly RMP, in patients
with advanced HIV infection and with diarrhea and evidence
of cryptosporidial infection. The bioavailability of INH is af-
fected more in rapid acetylators, and absorption of PZA and
EMB is also reduced. These findings confirm and extend a
previous observation of malabsorption of anti-TB drugs in
patients with HIV, TB, and diarrhea (7) and suggest that this
may be one of the factors affecting the success of anti-TB
therapy in this group. Further studies are required to assess
whether increasing the dosages of anti-TB drugs can help over-
come the effect of malabsorption in patients with advanced
HIV disease and to correlate plasma drug levels with treatment
outcome and emergence of mycobacterial drug resistance.
TABLE 2. Pharmacokinetics of rifampin
Group
Mean (95% CI)
Cmax
a (g/ml) Tmaxb (h) AUC0–8c (g/ml  h) AUC0–c (g/ml  h) Cld (ml/min) t1/2e (h)
Pulmonary TB (n  13) 7.2 (5.5–8.9) 2.4 (1.7–3.1) 33.0 (26.7–39.4) 44.6 (36.3–52.9) 15.0 (11.8–18.2) 3.0 (2.1–3.9)
HIV (n  13) 3.4f (2.5–4.3) 3.9 (2.7–5.0) 14.1f (9.9–18.2) 21.2f (14.8–27.6) 35.8f (27.3–44.2) 3.2 (2.6–3.7)
HIV-TB (n  15) 3.4f (2.7–4.2) 3.6 (2.7–4.5) 16.5f (12.4–20.6) 28.2f (18.1–38.4) 37.3f (21.4–53.2) 2.6 (1.7–3.5)
a Cmax, peak concentration.
b Tmax, time to attain Cmax.
c AUC, area under the plasma concentration versus time curve.
d Cl, clearance.
e t1/2, elimination half-life.
f P  0.05 (versus pulmonary TB results).
TABLE 3. Pharmacokinetics of isoniazid in rapid acetylators
Group
Mean (95% CI)a
Cmax (g/ml) Tmax (h) AUC0–8 (g/ml  h) AUC0– (g/ml  h) Cl (ml/min) t1/2 (h)
Pulmonary TB (n  5) 11.0 (7.6–14.3) 1.4 (0.6–2.2) 39.0 (23.7–54.4) 42.5 (25.9–59.2) 17.5 (11.5–23.5) 1.8 (1.5–2.0)
HIV (n  9) 7.3 (5.0–9.5) 1.8 (1.3–2.2) 24.2 (18.1–30.3) 26.2 (19.7–32.7) 28.3 (16.8–39.8) 1.9 (1.7–2.1)
HIV-TB (n  8) 7.0b (5.5–8.6) 1.4 (1.0–1.7) 22.9 (17.8–28.0) 24.4 (18.6–30.2) 34.5 (15.3–53.8) 1.9 (1.4–2.4)
a For definitions of abbreviations, see Table 2, footnote a.
b P  0.05 (versus pulmonary TB results).
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TABLE 4. Pharmacokinetics of isoniazid in slow acetylators
Group
Mean (95% CI)a
Cmax (g/ml) Tmax (h) AUC0–8 (g/ml  h) AUC0– (g/ml  h) Cl (ml/min) t1/2 (h)
Pulmonary TB (n  8) 12.9 (10.6–15.2) 1.6 (1.1–2.1) 61.1 (50.0–72.3) 79.6 (63.1–96.0) 9.7 (7.6–11.9) 3.1 (2.8–3.5)
HIV (n  4) 11.5 (9.4–13.6) 3.5 (0.5–6.6) 56.1 (42.2–70.0) 72.4 (56.4–91.8) 11.2 (8.7–13.7) 4.2b (3.8–4.6)
HIV-TB (n  7) 10.1 (8.3–11.8) 2.0 (1.3–2.7) 52.4 (44.9–59.8) 69.3 (62.7–75.8) 11.3 (9.7–13.0) 3.3 (2.8–3.7)
a For definitions of abbreviations, see Table 2, footnote a.
b P  0.05 (versus pulmonary TB results).
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